Claims for Patent: 11,013,733

Summary for Patent: 11,013,733

Title:	Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
Abstract:	Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
Inventor(s):	Susan Ashwell, Blythe Thomson, Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Wei Lu
Assignee:	Forma Therapeutics Inc
Application Number:	US16/431,588
Patent Claims:	1. A method of treating a patient diagnosed with a form of cancer characterized by an IDH1 mutation selected from the group consisting of R132G, R132S and R132L, the method comprising orally administering 150 mg BID of Compound 1, or pharmaceutically acceptable salt thereof, to the patient in need thereof: 2. The method of claim 1, wherein the patient is diagnosed with a cancer characterized by a concurrent mutation selected from the group consisting of FLT3, NPM1, CEBPA and TP53. 3. The method of claim 1, wherein the patient is diagnosed with a cancer that is not characterized by an IDH2 mutation. 4. The method of claim 1, wherein the patient is diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) characterized by the IDH1 mutation prior to the administration of Compound 1. 5. The method of claim 4, wherein the patient is diagnosed with MDS or AML further characterized by a concurrent mutation selected from the group consisting of FLT3, NPM1, CEBPA and TP53. 6. The method of claim 1, wherein the patient is diagnosed with a cancer characterized by a concurrent mutation selected from the group consisting of DNMT3A, NPM1, SRSF2, NRAS, RUNX1, ASXL1, FLT3, STAG2, TET2, SMC1A, SF3B1, U2AF1, PHF6, JAK2, MPL, NF1, ASXL2, BCOR, EED, WT1, CBL, CSF3R, ETNK1, PTPN11, ATM and TP53. 7. A method of treating a patient diagnosed with a hematological malignancy characterized by an IDH1 mutation selected from the group consisting of R132C, R132H, R132G, R132S and R132L and a concurrent FLT3 mutation, the method comprising orally administering 150 mg of Compound 1, or pharmaceutically acceptable salt thereof, BID to the patient in need thereof: 8. The method of claim 7, wherein the patient is diagnosed with a hematological malignancy characterized by a co-mutation selected from the group consisting of DNMT3A, NPM1, SRSF2, NRAS, RUNX1, ASXL1, STAG2, TET2, SMC1A, SF3B1, U2AF1, PHF6, JAK2, MPL, NF1, ASXL2, BCOR, EED, WT1, CBL, CSF3R, ETNK1, PTPN11, ATM and TP53. 9. The method of claim 7, comprising administering Compound 1 to the patient every day for at least 6 months. 10. The method of claim 7, wherein Compound 1 is administered to the patient as a single agent for the treatment of AML. 11. The method of claim 7, wherein the patient does not have an IDH-2 mutation. 12. A method of treating a patient diagnosed with a form of cancer characterized by an IDH1 mutation selected from the group consisting of R132G, R132S and R132L, the method comprising orally administering 150 mg of Compound 1 BID to the patient in need thereof: or pharmaceutically acceptable salt thereof, each day for a total of at least 6 months. 13. The method of claim 12, wherein the patient is diagnosed with a cancer characterized by a FLT3 mutation prior to the administration of Compound 1. 14. The method of claim 12, wherein the patient is diagnosed with a cancer characterized by a NPM1 mutation prior to the administration of Compound 1. 15. The method of claim 12, wherein the patient is diagnosed with a cancer characterized by a CEBPA mutation prior to the administration of Compound 1. 16. The method of claim 12, wherein the patient is diagnosed with a cancer characterized by a TP53 mutation prior to the administration of Compound 1. 17. The method of claim 12, wherein the patient is diagnosed with a cancer further characterized by both the mIDH1 mutation and a co-mutation selected from the group consisting of DNMT3A, NPM1, SRSF2, NRAS, RUNX1, ASXL1, STAG2, TET2, SMC1A, SF3B1, U2AF1, PHF6, JAK2, MPL, NF1, ASXL2, BCOR, EED, WT1, CBL, CSF3R, ETNK1, PTPN11, ATM and TP53. 18. The method of claim 12, wherein Compound 1 is administered in a R132X mIDH-1 Selective Inhibitor Therapy consisting of Compound 1 as a single agent. 19. A method of treating patients diagnosed with a cancer harboring an IDH-1 mutation, the method comprising orally administering 150 mg BID of Compound 1, or pharmaceutically acceptable salt thereof, to the patient in need thereof: 20. The method of claim 19, wherein the patient is diagnosed with acute myeloid leukemia (AML) and Compound 1 is administered to the patient in combination with azacitidine. 21. The method of claim 20, wherein the patient is treated for one or more 28-day treatment cycles, wherein: a. the azacitidine is administered to the patient at the dose of 75 mg/m2 for 7 days IV/SC per every 28-day cycle; and b. 150 mg of Compound 1 is administered BID to the patient every day throughout the one or more 28-day treatment cycles.